Exploring the role of the tumor microenvironment in refractory pituitary tumor pathogenesis
- 4 March 2023
- journal article
- review article
- Published by Springer Nature in Pituitary
- Vol. 26 (3) , 263-265
Abstract
Purpose Treatment-refractory pituitary tumors demonstrate characteristics resembling those of highly aggressive tumors, in which the local tumor microenvironment (TME) plays a dominant role in promoting aggressiveness and refractoriness. However, role of the TME in pituitary tumors is not well studied. Methods Literature on the TME and development of refractory pituitary tumors was reviewed Results TME harbors tumorigenic immune cells, cancer-associated fibroblasts (CAF), extracellular matrix, and other factors that have been shown to affect behavior of tumor tissue. For example, tumor-associated macrophages and tumor-infiltrating lymphocytes correlate with aggressive and invasive tumor behavior in nonfunctioning and growth hormone-secreting (GH) pituitary tumors, while CAF release of TGFβ, FGF2, cytokines, chemokines, and growth factors may promote treatment resistance, tumor fibrosis, and inflammation in prolactinomas and GH-secreting tumors. In turn, Wnt pathway activation can further promote cell growth in dopamine-resistant prolactinomas. Finally, proteins secreted by extracellular matrix are associated with increased angiogenesis in invasive tumors. Conclusion It is likely that multiple mechanisms, including TME, contribute to the development of aggressive refractory pituitary tumors. Given the increased morbidity and mortality associated with pituitary tumor refractoriness, more research on the role of TME is warranted.Keywords
This publication has 13 references indexed in Scilit:
- The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary CarcinomasFrontiers in Endocrinology, 2020
- Pituitary tumour fibroblast-derived cytokines influence tumour aggressivenessEndocrine-Related Cancer, 2019
- The Microenvironment of Pituitary Tumors—Biological and Therapeutic ImplicationsCancers, 2019
- miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinomaBrain Research Bulletin, 2019
- Beyond the tumour microenvironmentInternational Journal of Cancer, 2019
- Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinomaBrain Research, 2018
- A history of exploring cancer in contextNature Reviews Cancer, 2018
- Invasive Pituitary Adenoma-Derived Tumor-Associated Fibroblasts Promote Tumor Progression both In Vitro and In VivoExperimental and Clinical Endocrinology & Diabetes, 2017
- Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomasEndocrine, 2015
- The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomasMolecular and Cellular Endocrinology, 2015